In the 1960s, it had been observed that physical exercises could reduce the intraocular pressure (IOP) in patients with glaucoma. However, the effect of IOP reduction varied with exercise type and intensity, as well as the duration after exercise. Difference of lowering the IOP in glaucoma patients and healthy people were also observed. The mechanisms of reducing the IOP by exercise were very complicated and believed to be associated with the lower concentration of norepinephrine, the rising of colloid osmotic pressure, the co-action of nitric oxide and endothelin after exercise, and also related to the gene polymorphism of β2-adrenergic receptor. Physical exercise, such as jogging, walking and bicycle riding, could be suggested as a complimentary therapy in addition to the pharmaceutical and surgical therapies available for glaucoma patients, even though the mechanism for lowering IOP is not clear enough.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Effect of Blood Pressure on Rates of Progression in Focal Ischemic versus Generalized Cup Enlargement Glaucoma Phenotypes.
Ophthalmol Glaucoma
January 2025
Bascom Palmer Eye Institute, University of Miami, Miami, FL, USA. Electronic address:
Purpose: To investigate the impact of blood pressure (BP) on rates of retinal nerve fiber layer (RNFL) thinning in glaucomatous eyes with focal ischemic (FI) versus generalized enlargement (GE) optic disc phenotypes.
Design: Prospective cohort study.
Participants: The study included 122 eyes from 101 patients diagnosed with primary open-angle glaucoma.
Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.
Am J Ophthalmol
January 2025
Piedmont Eye Center, Lynchburg, Virginia.
Purpose: To evaluate the intraocular pressure (IOP)-lowering effect and safety of up to two bimatoprost implant administrations versus selective laser trabeculoplasty (SLT).
Design: Phase 3 (Stage 2), randomized, 24-month, multicenter, patient- and efficacy evaluator-masked, paired-eye clinical trial (NCT02507687).
Participants: Patients (n=183) with open-angle glaucoma or ocular hypertension inadequately managed with topical IOP-lowering medication for reasons other than efficacy.
Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma.
Sci Rep
January 2025
Department of Ophthalmology and ORL, Faculty of Medicine, Clinico San Carlos Hospital, Complutense University, Clinico San Carlos Hospital Health Research Institute (IdISSC), Calle del Prof Martín Lagos, s/n,, Madrid, 28040, Spain.
This study compared the efficacy safety profiles of the Xen 63 and Preserflo MicroShunt devices, both standalone, in patients with primary open-angle glaucoma (POAG). It is a retrospective and single-center study conducted on consecutive on patients with medically uncontrolled POAG who underwent either a standalone Xen 63 or a standalone Preserflo and had a 12-month follow-up visit. The primary outcome was the mean IOP at month-12.
View Article and Find Full Text PDFTreatment of pseudophakic aqueous misdirection syndrome.
Sci Rep
January 2025
Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010, Bern, Switzerland.
To describe the management and clinical course of 12 cases of pseudophakic aqueous misdirection syndrome (AMS). Twelve eyes of 12 Patients diagnosed with pseudophakic AMS between 2021 and 2022 were included. Best-corrected visual acuity, refraction, intraocular pressure (IOP), anti-glaucomatous medication, spectral domain ocular coherence tomography (SD-OCT) and postoperative complications were evaluated.
View Article and Find Full Text PDFNew treatments for glaucoma.
Curr Opin Ophthalmol
January 2025
New York Eye Surgery Center, New York City, New York, USA.
Purpose Of Review: This review highlights new Federal Drug Administration (FDA) approved glaucoma treatments to familiarize providers with immediately available options.
Recent Findings: New FDA-approved treatments include the bimatoprost implant, travoprost implant, direct selective laser trabeculoplasty (DSLT), and ocular pressure adjusting pump. The bimatoprost implant is approved for a single administration with effects lasting for about 1 year, as opposed to the nearly 3-year effect for the travoprost implant.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!